GLP-1 agonists increase satiety and reduce appetite, leading some patients to consume less fluid inadvertently
The combination is described in pharmacology literature as synergistic
However, an uncontrolled increase in their concentrations leads to a chain of unwanted radical reactions that target the main biomolecules (DNA, RNA, lipids, and proteins) and alters key processes such as nucleic acid oxidation, lipid peroxidation, thereby contributing to the loss of cellular architecture, to impaired cell signalling and, ultimately, to cell death [25, 46]
Topamax reduces appetite and increases feelings of fullness, which can lead to reduced calorie intake and weight loss
Abdul-Rahman T, Roy P, Bliss ZSB, Mohammad A, Corriero AC, Patel NT, Wireko AA, Shaikh R, Faith OE, Arevalo-Rios ECE, et al